Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImunonFRA:CBO0 -0.76%37 FCF Margin % is 0.00% as of Jun. 2026. GuruFocus rates FRA:CBO0 with a GF Score™ of 37/100 and a GF Value™ of €5.35 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 954 Biotechnology companies, Imunon ranks worse than 104821.7% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Imunon's Free Cash Flow for the
three
months ended in Jun. 2026 was €-2.63 Mil. Imunon's Revenue for the
three
months ended in Jun. 2026 was €0.00 Mil. Therefore, Imunon's FCF Margin % for the quarter that ended in Jun. 2026 was 0.00%.
The historical rank and industry rank for Imunon's FCF Margin % or its related term are showing as below:
During the past 13 years, the highest FCF Margin % of Imunon was -1436.00%. The lowest was -4673.00%. And the median was -3336.20%.
FRA:CBO0's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -77.885 * Ranked among companies with meaningful FCF Margin % only.
The historical data trend for Imunon's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CBO0 vs CVKD, RVPH, PMCB: FCF Margin % Comparison
For the Biotechnology subindustry, Imunon's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imunon FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Imunon's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Imunon's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imunon (FRA:CBO0) has a FCF Margin % of 0.00% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Imunon and its competitors. According to the industry distribution chart, Imunon ranks #999999 out of 954 companies in the Biotechnology industry.
Is Imunon's FCF Margin % too high?
Imunon's current FCF Margin % is 0.00%. Based on the distribution chart, Imunon ranks #999999 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Imunon has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Imunon's FCF Margin % compare to CVKD and RVPH?
According to the Biotechnology industry distribution chart, Imunon ranks #999999 out of 954 companies for FCF Margin %. This places Imunon in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Imunon and its competitors. Imunon's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imunon stock overvalued right now?
Based on GuruFocus' analysis, Imunon (FRA:CBO0) is currently considered Possible Value Trap. The stock's GF Value™ is €5.35, compared to a current price of €1.30 — trading 75.7% below its estimated fair value. The current FCF Margin % is 0.00%. Imunon's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Imunon (FRA:CBO0), the current FCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imunon (FRA:CBO0) Overvalued in 2026?
Based on GuruFocus' analysis, Imunon stock appears to be undervalued.
The current stock price of €1.30 is trading 75.7% below its estimated GF Value™ of €5.35.
GuruFocus considers Imunon to be Possible Value Trap.
Key valuation signals for FRA:CBO0:
FCF Margin %: 0.00%
GF Value™: €5.35 vs. price of €1.30 (75.7% below fair value)
No single metric tells the full story. See the FRA:CBO0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
37GF Score
Get the complete analysis for FRA:CBO0
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CBO0 has been successfully added to your 
